PAVmed to Present at the 28th Annual Oppenheimer Healthcare Conference
PAVmed Inc. (Nasdaq: PAVM, PAVMW) (the “Company”), a highly differentiated, multiproduct medical device company, today
announced that Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer, will present at the 28th Annual Oppenheimer
Healthcare Conference on Tuesday, March 20, 2018 at 3:55 p.m. Eastern time. Dr. Aklog will provide a corporate overview, discuss
the Company’s innovative business model and review PAVmed’s lead products. The conference will be held March 20-21, 2018 at the
Westin New York Grand Central in New York City.
Dr. Aklog’s presentation will be webcast live and available for replay in the Events and Presentations section of the Company’s
website at ir.pavm.com/events-presentations.
About PAVmed
PAVmed Inc. is a highly differentiated, multiproduct medical device company employing a unique business model designed to
advance innovative products to commercialization much more rapidly and with significantly less capital than the typical medical
device company. This proprietary model enables PAVmed to pursue an expanding pipeline strategy with a view to enhancing and
accelerating value creation. PAVmed’s diversified pipeline of products address unmet clinical needs encompassing a broad spectrum
of clinical areas with attractive regulatory pathways and market opportunities. Its three lead products provide groundbreaking
approaches to carpal tunnel syndrome (CarpX™), vascular access (PortIO™) and pediatric ear infections (DisappEAR™). The company is
also developing innovative products in other areas, such as medical infusions and tissue ablation, while seeking to further expand
its pipeline through engagements with clinician innovators and leading academic medical centers. For further information, please
visit www.pavmed.com.
Investors
LHA Investor Relations
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Media
PAVmed Inc.
212-949-4319
info@pavmed.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20180314005666/en/